Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Reader Login
  Users Online: 747Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2018| October-December  | Volume 9 | Issue 4  
    Online since October 4, 2018

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Show all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Effect of telmisartan on blood pressure in patients of type 2 diabetes with or without complications
Pradeep Gadge, Roshani Gadge, Nikita Paralkar, Preeti Jain, Vrunda Tanna
October-December 2018, 9(4):155-160
DOI:10.4103/picr.PICR_93_17  PMID:30319944
  1,636 275 -
Comparison of efficacy and safety of topical 1% nadifloxacin and tretinoin 0.025% combination therapy with 1% clindamycin and tretinoin 0.025% combination therapy in patients of mild-to-moderate acne
Swapnil Narayan Deshmukh, Vandana Avinash Badar, Manali Mangesh Mahajan, D Sujata Dudhgaonkar, Dharmendra Mishra
October-December 2018, 9(4):161-164
DOI:10.4103/picr.PICR_109_17  PMID:30319945
  1,023 178 -
Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot
Kiran Gordhanbhai Piparva, Gaurav Jansari, Anil P Singh
October-December 2018, 9(4):165-169
DOI:10.4103/picr.PICR_165_17  PMID:30319946
  903 203 -
Materiovigilance: An Indian perspective
Bikash Ranjan Meher
October-December 2018, 9(4):175-178
DOI:10.4103/picr.PICR_26_18  PMID:30319948
  826 151 -
Comparative evaluation of pharmacovigilance regulation of the United States, United Kingdom, Canada, India and the need for global harmonized practices
Mohit Hans, Suresh Kumar Gupta
October-December 2018, 9(4):170-174
DOI:10.4103/picr.PICR_89_17  PMID:30319947
  789 155 -
Drug-resistant tuberculosis – A ticking time bomb!
Srikanth Krishnamurthy
October-December 2018, 9(4):153-154
DOI:10.4103/picr.PICR_116_18  PMID:30319943
  691 211 -
Study designs: Part 1 – An overview and classification
Priya Ranganathan, Rakesh Aggarwal
October-December 2018, 9(4):184-186
DOI:10.4103/picr.PICR_124_18  PMID:30319950
  474 197 -
Investigator-initiated studies: Challenges and solutions
Mahanjit Konwar, Debdipta Bose, Nithya J Gogtay, Urmila M Thatte
October-December 2018, 9(4):179-183
DOI:10.4103/picr.PICR_106_18  PMID:30319949
  471 131 -
From “Glivec®” to “Prevnar 13®”: How strong is the Indian drug patenting system?
Gerard Marshall Raj
October-December 2018, 9(4):187-188
DOI:10.4103/picr.PICR_102_18  PMID:30319951
  229 56 -